For the quarter ending 2025-09-30, HRMY had $100,949K increase in cash & cash equivalents over the period. $108,663K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net product revenue | 239,455 | - |
| Cost of product sold | 59,643 | - |
| Research and development | 37,704 | - |
| Sales and marketing | 28,055 | - |
| General and administrative | 16,774 | - |
| Depreciation and amortization | 5,968 | - |
| Stock-based compensation | 10,824 | - |
| Interest expense | 3,621 | - |
| Interest income | 26,410 | - |
| Income tax expense | 16,625 | - |
| Other segment items | 15,106 | - |
| Net income | 50,865 | 85,336 |
| Depreciation | 7 | 13 |
| Intangible amortization | 5,961 | 11,922 |
| Acquired in-process research & development (ipr&d) expense | 15,000 | 15,000 |
| Stock-based compensation | 10,969 | 23,954 |
| Stock appreciation rights market adjustment | -145 | -110 |
| Debt issuance costs amortization | 161 | 329 |
| Deferred taxes | -3,881 | -10,796 |
| Amortization of premiums and accretion of discounts on investment securities | 336 | 904 |
| Other non-cash expenses | -9 | 932 |
| Trade receivables | 7,670 | 9,948 |
| Inventory | 782 | -1,098 |
| Prepaid expenses and other assets | -12,528 | 5,586 |
| Trade payables | -1,960 | 14,557 |
| Other liabilities | 28,026 | -12,483 |
| Net cash provided by operating activities | 108,734 | 113,314 |
| Purchase of investment securities | 24,281 | 43,032 |
| Proceeds from maturities and sales of investment securities | 19,563 | 40,937 |
| Purchase of property and equipment | 71 | 132 |
| Payment of upfront fee related to research collaboration, option and license agreement | 0 | 15,000 |
| Net cash used in investing activities | -4,789 | -17,227 |
| Principal repayment of long-term debt | 3,750 | 7,500 |
| Payments of employee withholding taxes related to stock-based awards | 0 | 2,341 |
| Proceeds from exercised options | 754 | 6,803 |
| Net cash used in financing activities | -2,996 | -3,038 |
| Net increase in cash, cash equivalents, and restricted cash | 100,949 | 93,049 |
| Cash and cash equivalents at beginning of period | 453,271 | - |
| Cash and cash equivalents at end of period | 647,269 | - |
Harmony Biosciences Holdings, Inc. (HRMY)
Harmony Biosciences Holdings, Inc. (HRMY)